Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria

Rhea-AI Summary

Halberd Corporation (OTC PINK:HALB) has achieved a significant milestone by eradicating 99.5% of antibiotic-resistant E. coli in vitro within 10 minutes using a patented laser method combined with metallic nanoparticles. This breakthrough, demonstrated with strains provided by the CDC, may revolutionize healthcare by enabling faster treatments and reducing hospitalizations without antibiotics. The ongoing research aims to continue testing and optimizing the technology for commercial application, with intentions to present findings to government agencies.

Positive

• Successfully eradicated 99.5% of antibiotic-resistant E. coli in under 10 minutes.
• Potential to revolutionize healthcare by allowing faster treatments and reducing hospital stays.
• Ongoing testing may enhance credibility and attract development partners.

Negative

• None.

Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in vitro

JACKSON CENTER, PA / ACCESSWIRE / February 21, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under 10 minutes. Halberd's patented extracorporeal process and patent-pending laser eradication method in conjunction with metallic nanoparticles eliminated 99.5% of the bacteria from the sample.

Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU stated, "Each of the 30 strains of bacteria provided by the CDC has demonstrated resistance to a wide variety of antibiotic treatments. The fact that we have been able to eliminate several, individually and in combination is a tremendous step forward. There is still much work to do to test the remaining strains of E. coli and the 30 strains of Candida auris fungus, but we are confident that our success will continue."

Dr. Sturrus, Chair and Professor, Physics, Astronomy Geology and Earth Science Department added, "Each experiment we run builds our knowledge base and uncovers new opportunities for improving the process, optimizing the experimental conditions, and bringing us another step closer to a commercial implementation of the technology."

William A. Hartman, Halberd's Chairman, President & CEO commented, "The ability to eradicate antibiotic resistant bacteria can have an astounding impact on healthcare. It could enable quicker treatments; shorter or eliminated hospitalizations; and reduced suffering and mortality. Most importantly, the eradication of dangerous antibiotic resistant bacteria and fungi takes place outside the body without the use of antibiotics.

"We plan to continue our accelerated eradication of all of the antibiotic resistant bacteria and fungi provided by the CDC and present our findings to the CDC and other government agencies at the appropriate time."

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC

About Youngstown State University
Youngstown State University is a public university in Youngstown, Ohio, and is composed of 5 undergraduate colleges. The University has over 150 undergraduate degree programs and 50 graduate degree programs serving over 12,000 students in studies up to the doctoral level. Beyond its current student body, the university has more than 125,000 alumni across the country and around the world.

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to four issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/740037/Halberd-Demonstrates-Simultaneous-Eradication-of-Multiple-Strains-of-CDC-Provided-Antibiotic-Resistant-Bacteria

FAQ

What recent breakthrough did Halberd Corporation announce regarding E. coli?

Halberd Corporation announced it eradicated 99.5% of a mixture of antibiotic-resistant E. coli strains in under 10 minutes using a patented laser method.

How does Halberd's method for eradicating bacteria work?

Halberd's method involves a patented extracorporeal process using laser eradication combined with metallic nanoparticles.

What are the implications of Halberd's recent findings on healthcare?

The findings indicate potential for quicker treatments, shorter hospitalizations, and reduced suffering from antibiotic-resistant infections.

When did Halberd Corporation make this announcement?

Halberd Corporation made the announcement on February 21, 2023.

What is the stock symbol for Halberd Corporation?

The stock symbol for Halberd Corporation is HALB.